完成换届的公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-033 广州迈普再生医学科技股份有限公司（以下简称"公司"、"迈 普医学"）于 2024 年 5 月 10 日召开了 2024 年第一次职工代表大会， 选举产生了第三届监事会职工代表监事；同日召开了 2023 年年度股 东大会、第三届董事会第一次会议、第三届监事会第一次会议，完成 了董事会、监事会的换届选举工作。现将具体情况公告如下： 一、公司第三届董事会组成情况 （一）第三届董事会成员 | 董事会 | 成员 | | --- | --- | | 非独立董事 | 袁玉宇（董事长）、王建华、骆雅红、龙小燕、袁美福、郑海莹 | | 独立董事 | 袁庆、陈晓明、陈建华 | 公司第三届董事会董事任期三年，自公司 2023 年年度股东大会 审议通过之日起计算。上述人员均符合担任上市公司董事的任职资格， 且三名独立董事的任职资格和独立性在 2023 年年度股东大会召开前 已经深圳证券交易所备案审核无异议。董事会中兼任公司高级管理人 员的董事人数未超过公司董事总数的二分之一，独立董事人数未低于 完成换届的公告 广州迈普再生医学科技股份有限公司 关 ...

董事长工作细则 MP-CG-033,V1.0 广州迈普再生医学科技股份有限公司 董事长工作细则 二〇二四年五月 第一章 总则 第一条 为进一步完善法人治理结构，明确广州迈普再生医学科技股份有限 公司 (以下简称" 公司")董事长的职责、权限，规范董事长与总经理之间的 职责分工，保证公司经营决策和日常管理的有机衔接。现依据《中华人民共和 国公司法》(以下简称"《公司法》")、《公司章程》、《董事会议事规则》等规 定，并结合公司客观情况和具体实际，制定本细则。 董事长工作细则 MP-CG-033,V1.0 第二条 本细则适用于本公司及合并范围内子公司，实施后，对公司及公司 董事长具有约束力。 第二章 董事长任职资格和义务 第三条 董事长由董事会以全体董事的过半数选举产生，对董事会负责。董 事长为公司法定代表人，依据《公司章程》和股东大会的授权，全面负责公司 法人财产事项和重大决策事项。除非出现董事长因违反国家法律法规、本细则 和《公司章程》规定而被解职或董事长自行辞职的情形，否则不得在任期内无 故罢免。 第四条 公司设董事长一名，任期三年，可连选连任。 第五条 董事长的任职资格 （一）有丰富的市场经济知识,具备正 ...

回购股份完成公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-035 广州迈普再生医学科技股份有限公司 关于回购股份完成暨回购实施结果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2024 年 2 月 22 日召开第二届董事会第二十一次会议，审议通过了《关 于回购公司股份方案的议案》，公司拟使用自有资金通过集中竞价交 易方式回购部分公司已发行的人民币普通股（A 股）用于员工持股计 划或者股权激励。公司拟用不低于人民币 1,000 万元且不超过人民币 2,000 万元（均含本数）。按照回购股份价格上限人民币 49 元/股， 回购金额下限人民币 1,000 万元测算，预计回购股份数量为 204,082 股，占公司当前总股本的 0.31%；按照回购股份价格上限人民币 49 元/股，回购金额上限人民币 2,000 万元测算，预计回购股份数量为 408,163 股，占公司当前总股本的 0.62%。本次回购股份的实施期限 为自公司董事会审议通过回购股份方案之日起不超过 12 个月，具体 ...

聘任公告 （二）证券事务代表、审计监察部负责人 关于聘任公司高级管理人员、证券事务代表及审计监察部负 责人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301033 证券简称：迈普医学 公告编号：2024-034 广州迈普再生医学科技股份有限公司（以下简称"公司"、"迈 普医学"）于 2024 年 5 月 10 日召开了第三届董事会第一次会议，审 议通过了《关于聘任公司总经理的议案》《关于聘任公司副总经理、 财务总监的议案》《关于聘任公司副总经理、董事会秘书的议案》《关 于聘任公司副总经理的议案》《关于聘任公司证券事务代表的议案》 《关于聘任公司审计监察部负责人的议案》现将具体情况公告如下： 一、本次聘任情况 （一）高级管理人员 广州迈普再生医学科技股份有限公司 龙小燕女士、李晓香女士均已取得深圳证券交易所董事会秘书资 格证书，熟悉履职相关的法律法规，具备与岗位要求相适应的职业操 守，具备履行职责所必需的专业能力与从业经验，其任职资格符合《公 司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号—创业板 ...

股东大会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-029 广州迈普再生医学科技股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）2023 年年度股东大会于 2024 年 5 月 10 日下午 14:30 以现场表决和网络投 票相结合的方式召开公司 2023 年年度股东大会。 1、会议召开时间：2024 年 5 月 10 日（星期五）下午 14:30； 2、会议召开地点：广州市黄埔区崖鹰石路 3 号迈普医学大厦会议 室。 3、会议召开方式：采取现场表决与网络投票相结合的方式。现场 会议召开时间：2024 年 5 月 10 日（星期五）下午 14:30。网络投票时 间：通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 5 股东大会决议公告 月 10 日上午 9:15-9:25， ...

回购股份进展公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-027 广州迈普再生医学科技股份有限公司 关于回购股份进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股份回购基本情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2024 年 2 月 22 日召开第二届董事会第二十一次会议，审议通过了《关于 回购公司股份方案的议案》，公司拟使用自有资金通过集中竞价交易 方式回购部分公司已发行的人民币普通股（A 股）用于员工持股计划 或者股权激励。公司拟用不低于人民币 1,000 万元且不超过人民币 2,000 万元（均含本数）。按照回购股份价格上限人民币 49 元/股， 回购金额下限人民币 1,000 万元测算，预计回购股份数量为 204,082 股，占公司当前总股本的 0.31%；按照回购股份价格上限人民币 49 元/股，回购金额上限人民币 2,000 万元测算，预计回购股份数量为 408,163 股，占公司当前总股本的 0.62%。本次回购股份的实施期限 为自公司董事会审议通过回购股份方案之日起不超过 12 个月 ...

证券代码：301033 证券简称：迈普医学 公告编号：2024-028 广州迈普再生医学科技股份有限公司 自愿增持公司股份时间过半的公告 关于公司部分高级管理人员自愿增持公司股份计划时 间过半的进展公告 公司董事、总经理王建华先生保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示 1、增持计划的基本情况：广州迈普再生医学科技股份有限公司 （以下简称"公司"）董事、总经理王建华先生拟自本次增持计划公 告披露之日起 6 个月内（即 2024 年 2 月 7 日至 2024 年 8 月 6 日，除 法律、法规及有关规定不得增持的期间外）通过深圳证券交易所交易 系统以集中竞价的方式增持公司股份，拟增持金额为人民币 25 万元 -50 万元。具体内容详见 2024 年 2 月 7 日披露的《关于公司实际控 制人、控股股东和部分董事、高级管理人员自愿增持公司股份计划的 公告》。 2、增持计划实施的进展情况：截至本公告披露日，王建华先生 的增持计划实施时间已过半。自增持计划公告之日至本公告披露日， 王建华先生通过深 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected increase in stock price relative to the benchmark index [12]. Core Insights - The company is set to see significant growth from new product launches, with a second growth curve beginning to take shape [8]. - In 2023, the company achieved a revenue of 231 million yuan, representing a year-on-year growth of 18.24%, and a net profit of 41 million yuan, up 13.89% [8]. - The company’s new products, particularly in the neurosurgery field, are expected to drive future growth, with a focus on expanding market share both domestically and internationally [9][15]. Financial Performance - The company reported a revenue of 57 million yuan in Q1 2024, a 28.59% increase year-on-year, and a net profit of 15 million yuan, up 91.19% [8]. - The revenue forecast for 2024-2026 is projected to be 290 million yuan, 388 million yuan, and 529 million yuan, with respective growth rates of 25.61%, 33.79%, and 36.34% [29]. - The net profit for the same period is expected to be 55 million yuan, 82 million yuan, and 121 million yuan, with growth rates of 35.27%, 47.61%, and 48.40% [29]. Product Analysis - The company’s main products include artificial dura mater patches, craniofacial repair systems, and new products such as absorbable regenerated oxidized cellulose hemostatic agents, which accounted for 60.47%, 26.41%, and 10.41% of revenue respectively [8]. - The craniofacial repair system saw a sales revenue of 60.97 million yuan in 2023, a 61.13% increase from the previous year, driven by growing demand in China [8]. - The absorbable regenerated oxidized cellulose hemostatic product has been used in over 100,000 clinical applications, breaking the long-standing import monopoly in the domestic market [8]. Market Positioning - The company has established a presence in nearly 90 countries and regions, with its products available in over 1,600 hospitals in China [9]. - The company is actively participating in bidding for medical glue products, which are expected to have significant market potential due to their unique properties [8].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% compared to the Shanghai Composite Index within the next six months [8][21]. Core Views - The company has shown strong revenue growth, with a reported revenue of 230.87 million yuan in 2023, representing an 18.2% increase year-on-year. The net profit attributable to shareholders was 40.88 million yuan, up 13.9% [15][17]. - The company is actively participating in centralized procurement, which is expected to accelerate product penetration and enhance market competitiveness. The introduction of new products is also anticipated to contribute significantly to revenue growth [6][17]. - The company’s sales and service network now covers nearly 90 countries and regions, with domestic and international revenues reaching over 180 million yuan and 50.046 million yuan, respectively, marking increases of 13.5% and 39.1% year-on-year [16][17]. Financial Performance - In 2023, the company achieved a revenue of 230.87 million yuan, with a year-on-year growth rate of 18.24%. The projected revenue for 2024 is 290.45 million yuan, reflecting a growth rate of 25.81% [10][17]. - The net profit attributable to shareholders for 2023 was 40.88 million yuan, with a projected increase to 52.35 million yuan in 2024, indicating a growth rate of 28.07% [10][17]. - The company’s earnings per share (EPS) are projected to be 0.79 yuan in 2024, increasing to 1.25 yuan in 2025 and 1.77 yuan in 2026, with corresponding price-to-earnings (P/E) ratios of 42.43, 26.89, and 19.01 respectively [10][17]. Business Segments - The primary revenue sources for the company are artificial dura mater (spinal) patches and craniofacial repair and fixation systems, accounting for 60.5% and 26.4% of total revenue, respectively. The dura mater patch segment saw a revenue decline of 3.5%, while the craniofacial segment experienced a significant growth of 61.1% [15][16]. - The commercialization of absorbable regenerated oxidized cellulose is expected to break the long-standing import monopoly in the neurosurgery market, with over 100,000 units used in clinical settings in 2023 [16]. - The company’s self-developed dura mater medical glue has unique properties that address existing product limitations, and its market penetration is expected to increase following the acquisition of necessary regulatory approvals [16].

Financial Performance - The company's revenue for Q1 2024 reached ¥57,206,084.70, representing a 28.59% increase compared to ¥44,485,769.60 in the same period last year[5] - Net profit attributable to shareholders was ¥14,944,754.94, a significant increase of 91.19% from ¥7,816,548.85 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥12,072,555.57, up 87.05% from ¥6,454,127.50 in the previous year[5] - Basic and diluted earnings per share both increased to ¥0.23, reflecting a growth of 91.67% compared to ¥0.12 in the same period last year[5] - The operating profit for the first quarter of 2024 was CNY 18,725,790.88, which is a significant increase from CNY 8,937,084.49 in the previous year[30] - The total operating revenue for the first quarter of 2024 was CNY 57,206,084.70, an increase of 28.6% compared to CNY 44,485,769.60 in the same period last year[28] - The total operating costs for the first quarter of 2024 were CNY 43,035,696.85, up 15.8% from CNY 37,145,242.79 in the previous year[28] - The net profit for the first quarter of 2024 reached CNY 14,944,754.94, representing an increase of 91.5% from CNY 7,816,548.85 in the same period last year[30] - The research and development expenses for the first quarter of 2024 were CNY 5,277,861.55, slightly down from CNY 5,661,139.07 in the previous year[28] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥778,037,172.67, a decrease of 1.13% from ¥786,969,032.68 at the end of the previous year[5] - The total current assets decreased slightly to CNY 265,898,793.41 from CNY 269,712,417.33, a decline of about 1.4%[25] - The company's inventory rose to CNY 30,344,255.45 from CNY 26,198,103.20, representing an increase of approximately 15.0%[25] - Non-current assets totaled CNY 512,138,379.26, down from CNY 517,256,615.35, indicating a decrease of about 1.0%[25] - The total liabilities as of the end of the reporting period were CNY 133,480,070.13, a decrease from CNY 151,110,819.27 in the previous year[28] - The total equity attributable to the parent company was CNY 644,557,102.54, an increase from CNY 635,858,213.41 in the previous year[28] Cash Flow - The net cash flow from operating activities was ¥15,888,191.38, down 18.25% from ¥19,434,599.35 in the same period last year[5] - Cash inflow from operating activities totaled $73,627,500.46, an increase from $66,508,610.90 in the previous period, representing an increase of approximately 3.34%[34] - Cash outflow from operating activities was $57,739,309.08, compared to $47,074,011.55 previously, indicating an increase of about 22.5%[34] - Net cash flow from operating activities decreased to $15,888,191.38 from $19,434,599.35, a decline of approximately 18.5%[34] - Cash inflow from investing activities was $116,272,060.74, down from $139,453,152.16, a decrease of about 16.6%[34] - Cash outflow from investing activities decreased to $99,454,056.35 from $164,086,920.91, a reduction of approximately 39.4%[34] - Net cash flow from investing activities improved to $16,818,004.39 from a negative $24,633,768.75, indicating a significant turnaround[34] - Cash flow from financing activities resulted in a net outflow of $9,983,352.37, compared to a larger outflow of $26,516,942.65 previously, showing a decrease of about 62.4%[36] - The net increase in cash and cash equivalents was $22,709,731.27, contrasting with a decrease of $31,925,042.71 in the prior period[36] - The ending balance of cash and cash equivalents rose to $49,380,615.16 from $12,837,726.43, reflecting a substantial increase[36] Shareholder Information - Major shareholders include Yuan Yuyu with 16.63% and Xu Tao with 16.53% of shares[14] - The top 10 shareholders hold a total of 50.61% of the company's shares, indicating significant ownership concentration[14] - Yuan Yuyu has pledged 4,910,000 shares, which is approximately 44.7% of his holdings[14] - As of March 31, 2024, the company reported that Yuan Meifu and his associates hold a total of 4,508,796 shares, representing 4.40% of the total shares[16] - Tang Ying and Ye Tao together hold 5.37% of the company after a transfer of 1,320,000 shares[16] - The company has a total of 10,987,847 shares held by Yuan Yuyu, with 10,922,547 shares subject to limited sale conditions[14] - The top 10 unrestricted shareholders include Shenzhen Kaiying Technology Co., Ltd. with 4,246,049 shares, representing 6.43%[14] - The report indicates that the company is actively managing its shareholder relationships and agreements to ensure compliance and transparency[16] - The company has not reported any additional related party relationships beyond those disclosed in the shareholder agreements[16] Other Information - The company implemented a second category of restricted stock for equity incentives starting in 2023, which positively impacted net profit growth[5] - The company reported a net profit of ¥1,769.73 million after excluding share-based payment expenses, marking a year-on-year increase of 126.41%[5] - The first quarter report was not audited, indicating that the financial figures are subject to further verification[37] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided data[28]